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Abstract 
Study of Gas Bubbles Stabilized by Surfactants for Use as  
Ultrasound Contrast Agents and Drug Carriers 
Boriphat Methachan 
Margaret A. Wheatley, PhD 
 
It has been well established that the vasculature in a tumor is more ‘leaky’ than 
that in normal tissue. The cutoff pore size is in the range of 380 and 780 nm depending 
on the tumor model and stage. It would be useful to fabricate an ultrasound contrast agent 
(UCA) that is smaller than the cut off pore size of a tumor allowing it to flow into the 
tumor.  This would facilitate better perfusion yielding better tumor imaging and lead to a 
new  and more effective way to deliver the chemotherapeutic drug for cancer treatment,. 
One of UCAs fabricated our lab was gas bubbles stabilized by surfactants. 
Specifically, perfluorocarbon (PFC) gas bubbles have been stabilized by the mixture of 
two surfactants. Two surfactant stabilized agents were developed: 1) a PFC gas bubble 
contrast agent, ST68, stabilized with Span60 and Tween 80 with a mean diameter of 
1.88±0.16 m and 2) SE61, with a Span60, d-α tocopheryl polyethylene glycol 1000 
succinate, or TPGS shell and comprised of gas bubbles with a mean diameter of 
1.31±0.20 m. These agents provided 20-30 dB ultrasound enhancements and the 
stability was dependent on the particle size that stabilized the bubbles. 
A new model was proposed to explain a previously unexplained observation, i.e., 
the fact that only combinations of solid Span with Tween (a liquid) can form 
microbubbles, liquid Spans do not.  Various studies were conducted which indicate that 
the bubbles stabilized by solid particles is a realistic possibility. These included the 
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behaviors of the bubbles as they dried, the fact that larger Span particles produced more 
robust bubbles and preliminary scanning electron microscopic evidence. 
A substantial number of nanobubbles were fabricated for SE61 compared with 
ST68. These nanobubbles still retained good echogenicity, but they were less stable 
(1.75±0.24 min) as compared to the microbubble (16.45±1.56 min).  
ST68 with a bubble diameter ranging from 955 nm to 2.67 m and SE61 with 
bubble sizes ranging from 342 nm to 900 nm were used to see if the smaller sized 
bubbles would yield better ultrasound imaging for tumor perfusion deeper into the tumor 
bed. Power-Doppler ultrasound imaging was used in vivo to analyze the tumor perfusion 
for both agents in an animal (rat) study. Tumor coverage and time were plotted and 
analyzed by comparing parameters in wash-in and wash-out phases. The results showed 
that both agents gave good tumor coverage. However, SE61 provided better perfusion 
imaging than ST68 and took longer to clear out of the tumor. It should be noted that 
Delta-projection is better in portraying the vasculature of the tumor as compared to 
Power-Doppler. 
By using Nile Red, a hydrophobic fluorescent solvatochromic probe, we showed 
that a hydrophobic drug could intercalate into the hydrophobic portion of the surfactants 
in the bubble shell to make drug delivery possible. The subsequent experiments showed 
that Paclitaxel, a promising anti-tumor agent with poor water solubility, intercalated into 
the bubbles at the concentration around 3.8 g/ml. This concentration was close to 100 
times higher than the suggested effective concentration from other studies. 
 
 
 
 
 1. INTRODUCTION 
 
Cancer is caused by uncontrolled growth and spreading of abnormal cells, and if 
the spread is not controlled, it can result in death. A total of 577,190 Americans are 
expected to die of cancer and about 1,638,910 new cancer cases will be diagnosed in 
2012. [1] The estimation of overall costs of cancer by The National Institutes of Health 
was $228.1 billions in 2008. Cancer killed 7.6 million people around the world in 2008 
and the number is expected to rise to 17.5 million by 2050. Available treatments are 
surgery, radiotherapy, chemotherapy, hormone therapy, and immunotherapy. [2] For the 
most effective result, early and precise detection are the most important factors. 
The long term-goal of this study is to develop a surfactant-stabilized diagnostic 
ultrasound contrast agents that can also act as a targeted drug carrier for cancer therapy. 
The advantage of this combination makes it possible for real time diagnostic imaging and 
ultrasound-triggered drug release. As a function of the focused ultrasound, not only 
specific site imaging can be performed but also the drug can be delivered directly to the 
cancer cells to improve drug dosage compared with systemic administration. The result 
of this will be to reduce drug toxicity and undesired side effects that are caused by a 
typical treatment, thereby measurably improving the efficacy of treatment and the quality 
of life for the cancer patient.  
There are four specific aims for this study. 
 
Specific Aim 1: Development and testing of a new model to elucidate the mechanism of 
stabilization of the gas bubbles by the surfactants. 
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 Previously, a mixed surfactants model had been proposed for the structure of the 
agent shell. [3] This model, however, cannot adequately explain why the microbubbles 
can be stabilized, neither can stability be inspection of the Hydrophilic-Lipophilic 
Balance (HLB) of the constituent molecules.  From this study, it was noticed that stability 
only occur when mixing at least one solid surfactant with another surfactant. The 
hypothesis of the particle-stabilized foams will be examined in order to explain this 
unresolved question. The key parameters that play an important role in the surfactant-
stabilized gas bubbles, were determined. The results were analyzed to test for a fit with 
the suggestion that the bubbles are stabilized in accordance with the “particle-stabilized 
foams” theory. The importance of the correct model will be useful for further study and 
expanding the therapeutic applications of the surfactant-stabilized gas bubbles. 
 
Specific Aim 2: Investigate the method for increasing the proportion of the nano-sized 
bubble component relative to population created using the standard method. 
The difference between blood vessels that develop to supply a tumor and normal 
physiological vessels is the tendency to be ‘leaky’. These gaps in the vessel walls have 
been reported between 380 and 780 nm depending on the tumor model and stage. 
However, the previous study in our lab for the surfactant- based contrast agents mostly 
dealt with microbubbles. [3-8] The nanobubbles were fabricated in conjunction with the 
microbubbles and were then separated by buoyancy and characterized. [9, 10]  In this 
specific aim, the method of increasing the proportion of nano-sized contrast agent was 
investigated with a view to elucidating the contribution of each component, and use of a 
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new surfactant combination which may lead to a method of increasing the proportion of 
the nano component. 
 
Specific Aim 3: In-vivo tumor perfusion study comparing the agents with different 
nanobubble populations.   
With success in fabricating agent with increased nano-sized bubble population, 
the agents were tested in vivo to see if the agent that consisted of smaller bubbles would 
be better in ultrasound imaging and tumor perfusion. Our hypothesis is the smaller 
bubbles will provide better tumor perfusion. In this specific aim, the two agents that have 
different size distributions were compared with respect to the tumor perfusion imaging in 
two modes of ultrasound imaging: Power Doppler and B-mode for -projection. The 
tumor perfusion was calculated from the percentage area of flow plot and a first-pass 
kinetics gamma-variate function was used to calculate the perfusion ratio.  
 
Specific Aim 4: Develop a method to intercalate a hydrophobic drug into the agents. 
Because the long-term goal of this study is using the UCA as a drug carrier for 
ultrasound triggered drug release, the studies in this specific aim were tested to see if it 
was possible to load drugs into the bubble shell. The hydrophobic dye, Nile Red, was 
used as a hydrophobic drug model.  The hypothesis is that the hydrophobic portions of 
the amphipathic molecules that make up the shell of the agents could be sites to 
intercalate a hydrophobic drug. The success in loading Nile Red led to testing the loading 
of Paclitaxel. The drug-loaded agents were tested for their echogenicity and the amount 
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of Paclitaxel loading was measured. The success of the Paclitaxel loading portends the 
possibility of drug delivery using surfactant stabilized bubbles as drug carriers. 
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2. BACKGROUND AND LITERATURE REVIEW 
 
 In this chapter the background of this study will be discussed in conjunction with 
a review of the literature which bears on key components of the study. These components 
include ultrasound, ultrasound contrast agents, foam and bubble stability, and ultrasound 
used in drug delivery.  
 
2.1 Ultrasound 
 Ultrasound is simply sound waves that are comprised of waves of compression 
and decompression passing through a medium (e.g. air or water), traveling at a fixed 
velocity. The frequencies of diagnostic ultrasound are in the range of 1 - 15 MHz. The 
diagnostic applications of ultrasound imaging have been expanding and offer many 
advantages over other imaging modalities. These advantages include safety, portability, 
acquisition of real time images, and relatively low cost.  
 Ultrasound imaging works by a transducer transmitting acoustic waves through a 
body. Some of the waves reflect back to the transducer due to differences in acoustic 
impedance. Images are then generated from the reflected waves. The acoustic impedance 
(z) depends on density of the medium () and the speed of sound in the medium (c). The 
acoustic impedance can be defined as: [11] 
     z =  x c      Eq 2.1 
 The reflection occurs when an ultrasound wave passes from one medium to a 
second medium. A reflection coefficient (R) is a measure of the degree of reflection, 
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which R = 1 denotes 100% wave reflection, while R = 0 denotes 100% transmission of 
the wave. The reflection coefficient R equals: [11] 
      
     
     
      Eq 2.2 
 There are several modes of ultrasound imaging. Some of these modes are: 
 A-mode: A-mode (amplitude mode) is the simplest mode. It is an amplitude 
modulation scan that gives the information in a one dimensional form. A single 
transducer scans a line through the body with the reflections plotted on screen as a 
function of depth. 
 B-mode: B-mode (brightness mode) or grey scale is when a linear array of 
transducers simultaneously scan a plane through the body that can be viewed as a two-
dimensional image on screen. 
 Doppler mode: The image of this mode can be constructed by means of the 
Doppler Effect in measuring and visualizing blood flow.  
 Harmonic mode: In this mode, a fundamental frequency is emitted and a 
harmonic overtone is detected to improve resolution. 
  
2.2 Ultrasound Contrast Agents 
The ultrasound technique is limited in its ability to distinguish between diseased 
and normal tissue. It is similarly limited in distinguishing between two soft tissue 
boundaries. However, with the utilization of contrast agents such soft tissue boundaries as 
the myocardium and tumors can be distinguished. [12] 
Ultrasound contrast agents are used to enhance the backscattered signal, 
improving resolution. In general, contrast agents are comprised of stabilized gas bubbles. 
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There are several micron-range contrast agents both in clinical use and in development 
Table 2.1 shows some examples of microbubble contrast agents. [13, 14] 
 
Table 2.1 Microbubble contrast agents  
Name Shell Gas 
Albunex Albumin Air 
Definity Lipid/surfactant Octafluoropropane 
Echovist Galactose Air 
Echogen Sucrose Dodecafluoropentane 
Imagent Lipid/surfactant Perfluorohexane/nitrogen 
Levovist Galactose Air 
Optison Albumin Octafluoropropane 
Sonazoid Lipid/surfactant Perfluorobutane 
Sonovue Lipid Sulfur hexafluoride 
 
Due to the high acoustic impedance mismatch between gases and blood or soft 
tissue, the acoustic backscatter of microbubbles is greater than the backscatter of blood 
and the majority of other tissues and organs. This property makes microbubbles useful as 
contrast agents for ultrasound imaging. 
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Stabilized gas bubbles based on surfactant-shells have been developed. [3, 4] 
These gas bubbles are meeting with essential clinical requirements, which are that they 
are non toxic, biocompatible, less than 8 m in diameter in order to traverse the 
capillaries in the pulmonary bed, and stable enough to perfuse the tissue and last the 
duration of imaging. [15] A mixture of two non-ionic surfactants, Span and Tween, was 
used to stabilize gas bubbles.  Both surfactants are fatty acid esters of sorbitan, which 
have a hydrophobic tail group, for example monolaurate (C11: Span 20 and Tween 20), 
monopalmitate (C15: Span 40 and Tween 40), monostearate (C17: Span 60 and Tween 
60), and monooleate (C17: Span 80 and Tween 80). All chains are fully saturated except 
for the oleate chains which contain a single cis-double-bond. The difference between 
Tween and Span is that Tween has the hydrophilic sorbitan head group modified with 
polyethyleneoxide groups (Figure 2.1) and this greatly increases the polarity that makes 
the molecule more water-soluble. It should be noted that the stable microbubbles are 
successful only in the combination between solid Span (Span 40 and Span 60) and almost 
all types of Tween. The trioleate series of Span 85 and Tween 85 do not stabilize bubbles 
in any combination, which is not unexpected since the three oleate fatty acid chains that 
they possess are extremely bulky (Table 2.2). [4] Also, different combinations of 
surfactant and different gases affect the backscatter from the microbubbles. [6] 
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(a) 
 
(b) 
Figure 2.1 Molecular structure of Span 60 (a) and Tween 80 (b) [6] 
 
Table 2.2 The stability of microbubbles, which were stabilized with different combination  
of Span and Tween [6] 
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The previous model for microbubbles stabilized by Span 60 and Tween 80 is 
shown in Figure 2.2 [3, 4], and was developed using a Langmuir trough. The model 
suggested that the stability of the bubble is due to the fact that the bulky head of Tween is 
stabilized by the presence of Span in the shell which causes the reduction of the repulsive 
force in Tween molecules by hydrophobic attraction between the tail groups. This model, 
however, cannot explain why the microbubbles are stable only with solid Span. One 
explanation proposed in this work could be the additional stability due to the presence of 
nano-sized particles of Span. Understanding particle-stabilized foams might help us to 
understand the stability of these particular contrast agent microbubbles. 
 
 
Figure 2.2 The previous proposed model for microbubbles stabilized by Span 60 and Tween 80 [6] 
 
2.3 Foam and Bubble Stability 
Foams can be considered thermodynamically unstable. However, kinetic 
mechanisms involved with breakdown can be so slow that the foams can be thought of as 
having metastability. Depending on the system, some foam can breakdown within an 
hour but in some case, the foams have been stable for more than 3 weeks. [16-24] The 
primary processes for instability in foams are drainage and coalescence. [25] Water 
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drainage is most significant in foam stability. This is caused by gravity-induced 
movement due to the density differences between gas and water. Coalescence comes 
about by the binding of two or more foam bubbles, where the interfacial film drains and 
is eventually ruptured forming a single larger bubble. 
Another important form of foam instability is disproportionation. This is a process 
that occurs when the gas molecules diffuse between bubbles. The diffusion flux generally 
results in the growth of larger gas bubbles and the shrinking of the smaller bubbles due to 
the increasing of Laplace pressure of the smaller bubbles. [26, 27] The Laplace pressure 
is a pressure difference between inside and outside the bubble and can be calculated by: 
   
R
PPP outsideinside
2
     Eq 2.3 
where  is the surface tension and R is the bubble radius.   
 
It is normally necessary to add some component to help stabilize foams. In air-
water system, foaming agents are required to first produce the conditions that will create 
foams and also stabilize them. Without the foaming agent, ‘clean’ air bubbles passed 
through water will burst immediately on drainage of water in a thin film [28]. The 
foaming agents can be surfactants, polymers or larger proteins. Surfactants adsorbed to an 
air-water interface stabilize foam by reducing the free energy involved with producing a 
high surface area, resulting in reduced interfacial surface tension. Polymers and proteins 
facilitate stability largely through electric and steric repulsion. [25] 
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2.4 Particles-stabilized Foams 
There is a theory that attempts to explain how particles can act as surfactants in 
stabilizing foams and emulsions, labeled “particle-stabilized foam” theory. [25, 29, 30] 
The solid particles can function in the same ways as surfactants but some behaviors are 
different. For example, particles do not always assemble the same way that surfactant 
molecules do when they form micelles, and, hence the solubilization phenomena (i.e. the 
ability of dilute surfactant solutions to solubilized water-insoluble substances to form 
stable systems [31]) is absent in the particle case. When the spherical particles adsorb to 
interfaces (Figure 2.3), the contact angle  which the particle makes with the interface is 
important. [29] For hydrophilic particle, the contact angle measured into the aqueous 
phase is normally less than 90
o
 and the larger fraction of the particle resides in the water. 
By analogy with surfactants, the monolayer will curve to make the larger area of the 
particle surface remain on the external side, giving rise to air or oil-in-water emulsions 
for <90o. There will be an opposite effects for hydrophobic particles, which are suitable 
for water-in-air or water-in-oil emulsions with a contact angle which is greater than 90
o
. 
Our system involves oil (PFC) in water emulsion, and would therefore suggest the 
presence of hydrophilic particles, which is not the case with Span. An alternative 
situation must therefore exist. 
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Figure 2.3 Position of a small spherical particle at the interface for a contact angle (measure through 
the aqueous phase) less than 90
o
 (left), solid-stabilized aqueous foam or o/w emulsions may form.  For 
>90o (right), solid –stabilized aerosols or w/o emulsions may form. (Adapted from [29]) 
 
The physical reason for the better efficiency of particles over surfactants in 
stabilizing foams is their attachment energy which can be up to several thousand kT per 
particle, where k is the Boltzmann constant and T is the absolute temperature, compared 
to only a few kT per surfactant molecule. [32] Because of this high energy attachment at 
the interface, the particle adsorption can be considered as irreversible. [33] The required 
energy to remove the particle from its equilibrium position at the interface to the bulk 
liquid phases is [34] 
22 )cos1(   rGremove                 Eq 2.4  
   
where r is the radius of the spherical solid particle; σ is the interfacial energy;  is the 
Gas or Oil 
Gas or Oil 
Gas or Oil 
Water 
Water 
Water 


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contact angle; sign’+’ refers to particle removal into gas phase, while sign ‘-‘ refers to the 
removal into the liquid phase. Equation 2.4, however, does not say anything about the 
stability of the thin liquid layer between bubbles which are stabilized by particles. To 
answer this question, the maximum capillary pressure was introduced and can be 
calculated from [34] 
)(cos
2max z
R
pPc  

    Eq 2.5 
where p and z are the parameters for different particle arrangements, which are shown in 
Figure 2.4 [34]. For example in the case of a close-packed bilayer, if <90op = 4.27 and 
z = 0.405 but for 90
o≤<129.3o, p = 2.73 and z = 0.633. With equation 2.4 and 2.5, 
Kaptay can make the calculations that agree with the experimentally observed optimum 
contact angle interval. [34] 
 
Figure 2.4 Possible mechanisms of liquid film stabilized by: (a) a monolayer of particles; (b) a bilayer 
of close-packed particles and (c) a network of particle aggregated inside the film. [35] 
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Another approach to particle-stabilized foams is by changing the hydrophilicity 
and wetting properties of the solid particles so as to favor their attachment at the gas-
liquid interface. One possibility is mixing the colloid particles with amphiphilic 
molecules or surfactant. [30] This scenario should fit well in our study using the 
hydrophobic particles of Span mixed with Tween. The model and picture of this type of 
the system are shown in Figure 2.5 and 2.6. 
 
 
Figure 2.5 Possible approaches to attach colloidal particles at gas–liquid interfaces by tuning their surface-
wetting properties. a) Schematic illustration of the stabilization of gas bubbles with colloidal particles (the 
particle size is exaggerated for clarity). b) The adsorption of partially lyophobic particles at the gas–liquid 
interface, c) The approaches used to tune the wetting properties of originally hydrophilic particles to 
illustrate the universality of the foaming method developed. The same principles can be easily extended to 
other types of particles, by using different surface modifiers as well as liquid and gaseous phases. [30] 
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Figure 2.6 Hierarchical features of the particle-stabilized foams containing short amphiphilic molecules. 
High-volume macroscopic foams (a) with bubble sizes within the range 10–50 mm (b) are formed through 
the adsorption of submicrometer-sized colloidal particles at the air–liquid interface (c). Particles attach at 
the air–water interface as a result of the surface hydrophobicity imparted by the adsorbed amphiphilic 
molecules, as indicated schematically in (d). The confocal images shown in (b) and (c) were obtained after 
dilution of concentrated foams (inset in b) containing fluorescently labeled silica particles and hexylamine 
as amphiphile. [30] 
 
2.5 Ultrasound and Drug Delivery 
The goal of controlled drug delivery is to improve the efficiency of drug treatment 
in the region of the disease and reducing undesirable side effects in the healthy tissues. 
For this reason, many studies are investigating the application of an external trigger to 
locally release drugs. Ultrasound waves have advantages as a controlling field for drug 
delivery since they can be focused at a given site.  
Ultrasound is widely applied in medicine and allows easy focusing and 
penetration deep into the body. There is some discussion that the effect of ultrasound 
alone has been shown to increase cell membrane permeability. [36] The presence of 
ultrasound energy provides highly efficient ways of perturbing cell membranes and 
increasing their permeability. With the added ability of microbubbles to act as cavitation 
nuclei, the subsequent bubble collapse increases cell membrane permeability, and the net 
result is that the use of microbubbles with ultrasound has a significant additive effect. 
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[36] Normally, pharmaceutical drug carrier particles are too large to cross the endothelial 
layer and escape from the blood stream. The destruction of microbubbles has been shown 
to increase vessel permeability and create conditions to help overcome the endothelial 
lining barrier in the targeted tissue. [37] However, there is some size limitation for the 
drug carrier to release into specific targeting sites. The nano-sized bubbles, therefore, will 
be produced to overcome this limitation. 
New vasculature is needed to supply the rapidly dividing cells of a tumor with 
nutrients during tumor development, and the growth process for new vessels is known as 
angiogenesis. [38] One consistent difference between tumor blood vessels and normal 
physiological vessels is the tendency to be ‘leaky’. [39] It has been reported that the pore 
cutoff size of several tumor models rages between 380 and 780 nm [40, 41], but some 
studies suggested the pore cutoff size lies around 400 nm. [42] Therefore, if we want the 
carriers to exit the blood stream, it is important to develop drug carriers that are smaller 
than these suggested pore cutoff sizes. Nanoparticles can deliver anti-cancer drugs 
through these pores by targeting specific cancer tissue or cells, while protecting the drug 
from inactivation during transport.  
There are extensive studies on polymeric drug-loaded nanoparticles. [43] One 
study shows that combining ultrasound with nanoparticles increasing drug susceptibility 
of cancer cells. [44] A mixture of nanoparticles stabilized by biodegradable block 
copolymers and their micelles as drug-loaded carriers for ultrasound targeted 
chemotherapy has been achieved. [45] The main idea is that the micelles and 
nanobubbles can go through defective endothelial gaps to the tumor and coalescence into 
larger, highly echogenic microbubbles in the tumor tissue. With the tumor-directed 
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ultrasound, the microbubbles cavitate and collapse resulting in a release of the drug and 
enhanced intracellular drug uptake by the tumor cells. This system, however, has some 
disadvantages. It is suggested that the bubbles are getting irreversibly bigger when heated 
to the physiological temperature (i.e. 37C) because the vaporization of Perfluoropentane 
which they contain. [45]  
 
 
Figure 2.7 Schematic representation of a drug targeting though the defective tumor microvasculature 
using an echogenic drug delivery system. The system consists of polymeric micells (small circle, 
nanobubbles (stars) and microbubbles (large circles). [45] 
 
2.6 Nile Red 
A hydrophobic dye, Nile Red, (molecular weight MW:  318.375) is a popular 
fluorescent probe in biological and medical research used to localize and quantify lipids, 
to stain proteins, and to detect ligand-binding to enzymes. It is also used as a florescent 
dye probe for the study of micelles. [46-48] Nile Red has fluorescence that is strongly 
dependent on the polarity of its environment. [49] In DMSO, Nile red has Abs/Em = 
552/636 nm. In cholesterol ester droplets or hydrocarbon solvents, Nile red fluoresces 
yellow-gold (528 nm), while in ethanol or phosphatidylcholine vesicles, the dye 
fluoresces red (>610 nm). [50] In aqueous media, it is relatively insoluble and 
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fluorescence is strongly quenched. Chiefly because the color of the observed fluorescence 
is directly dependent on the hydrophobicity of the surrounding and it is highly 
hydrophobic, Nile Red will be chosen as a model for a highly hydrophobic drug 
Paclitaxel (MW = 853.9) that can intercalate into the hydrophobic shell of our contrast 
agent. 
 
  
(a) (b) 
Figure 2.8 Molecular structure of (a) Nile Red and (b) Paclitaxel  
 
2.7 Paclitaxel (Taxel®) 
Paclitaxel is a promising anticancer drug with special effects against a wide 
spectrum of cancers, including breast, ovarian, lung, colon, head and neck cancer, 
multiple myeloma, melanoma, and Kaposi’s sarcoma. [2] It was approved by Food and 
Drug Administration for the treatment of ovarian cancer in 1992, advanced breast cancer 
in 1994 and early-stage breast cancer in 1999. Because of its highly lipophilic nature, it is 
insoluble in water, and this leads to one of the main limitations of Paclitaxel, is it is 
difficult to administer to the patient. A commercially available dosage form is the 
solution of Paclitaxel in Cremophor EL (polyethoxylated castor oil) and dehydrated 
alcohol. [2, 51, 52] Although it has been used to administer other drugs, the amount of 
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the Cremophor required to deliver Paclitaxel is significantly higher than those other 
drugs, and this leads to increased patient toxicity and can lead to hypersensitivity 
reactions in certain individuals. Since Paclitaxel is one of the most commercially 
successful anticancer drugs, it will be important to develop a better dosage form to avoid 
the toxic Cremophor, and this may have enormous clinical and commercial value. 
There are many alternative Paclitaxel administration suggestions [52, 53] but one 
interesting suggestion is Paclitaxel-loaded microspheres. It has been shown that 
acoustically active lipospheres, the microbubbles surrounded by a shell of oil and lipid, 
can be used as Paclitaxel delivery vehicles. [54] Because of its highly hydrophobicity, 
Paclitaxel will be chosen for loading into our contrast agent.  
 
2.8 Vitamin E TPGS (d--tocopheryl polyethylene glycol 1000 succinate) 
TPGS is a water-soluble form of natural source vitamin E. It is very stable and 
does not hydrolyze under normal conditions. TPGS can be prepared by esterifying the 
acid group of d-alpha-tocopheryl acid succinate with polyethylene glycol 1000. The 
molecular structure of TPGS is shown in Figure 2.9. It can be used as an emulsifier, drug 
solubilizer, absorption enhancer, and as a vehicle for lipid-base drug-delivery 
formulations.  
TPGS has found wide utility in pharmaceutical formulations including improving 
drug bioavailability, emulsion vehicle, reducing drug sensitivity on skin or tissues, and 
water-soluble source of vitamin E. There are some studies that show the possibility of 
PLGA nanoparticles containing vitamin E TPGS to control and release Paclitaxel. [53, 
55]  These studies also show that the biodegradable polymers containing TPGS give 
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higher Paclitaxel encapsulation efficiency. For these reason, and the structural similarity 
to Tween, TPGS is chosen for investigation as a possible co-surfactant in our bubbles, 
with the aim to produce a significant nano population through closer packing of the head 
groups. 
 
 
 
Figure 2.9 Molecular structure of d--tocopheryl polyethylene glycol 1000 succinate (TPGS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
3. MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Surfactants 
There are three non-ionic surfactants used in this study. Span60 (sorbitan 
monostearate), and Tween80 (polyoxyethylene-sorbitan monooleate) were purchased 
from Sigma (St. Louis, MO). Vitamin E TPGS (d-a Tocopheryl polyethylene glycol 1000 
succinate) NF grade was purchased from Eastman (Kingport, TN). All surfactants were 
used without further purification. 
 
3.2.2. Other Chemicals 
 PFC gas (octafluoropropane) was purchased from American Gas Group (Toledo, 
OH). Paclitaxel was purchased from LC Laboratories (Woburn, MA) and used without 
purification.  Acetonitrile HPLC Grade and Ethyl Acetate HPLC Grade were purchased 
from Fisher Scientific (Fair Lawn, New Jersey).  All other chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO). 
 
3.2 Methods 
3.2.1 Microbubble Contrast Agent Fabrication 
 Ultrasound contrast agents were fabricated by a procedure that modified the 
procedure of previous studies. [9, 10] The Standard Operating Procedure (SOP) for 
preparing the surfactant stabilized UAC is explained in the appendix A.1 for ST68 and 
A.2 for SE61. Briefly, the desired amount of Span 60 with Tween 80 for ST68 and Span 
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60 with TPGS for SE61 and Sodium Chloride were added into 50 ml PBS. The mixture 
was heated with a constant stirring until all chemicals were dissolved. The solution was 
then sterilized for 35 min at which point it was cooled to room temperature with constant 
stirring. To generate the bubbles, the cooled solution (held in an ice bath) was sonicated 
at 110 W for 3 min (Misonix Inc. CL4 tapped horn probe with 0.5” tip, Farmingdale, NY) 
in the presence of PFC gas to be entrapped. The bubbles were then washed three times 
with cold (4 
o
C) 50 ml PBS in a cold (4 
o
C) 125 ml separation funnel.  The solution is 
allowed to separate into three distinct layers (35 min for ST68 and one hour for SE61) 
and the bottom layer consisting of unused surfactants is discarded with each wash. After 
the last wash, the microbubbles at the middle layer were collected. 
 
3.2.2 Drug Loading UCA Fabrication 
 The Paclitaxel loaded UCA was fabricated followed the SOP for fabricating UAC 
with minor modifications. Paclitaxel was added to the mixture before sonication, after it 
cooled down to room temperature after the sterilization step. The mixture was heated and 
boiled with constant stirring for 30 min and cooled to room temperature.  After that, 
sonication and washing in the standard procedure were continued.   
 
3.2.3 Characterization of UCA  
3.2.3.1 Size Distribution 
 Particle and bubble sized distributions were done by using a Malvern Nano 
ZetaSizer (Worcestershire, United Kingdom). For the particle size, the amount of 50 L 
solution was diluted with 950 L PBS before the measurement. For bubble size 
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distribution, 0.2 ml of the bubbles were added to 10 ml volume metric flask, then 10 ml 
volume was made up by cold (4
o
C) PBS, which was used for an acoustic testing. All 
volume values were quoted back to the original volume after preparation and before 
dilution. 
 
3.2.3.2 Acoustic Testing of UCA in vitro 
 A one-dimensional pulsed A-mode US set-up (Figure 3.1) with a single element, 
broadband, 12.7 mm element diameter, 50.8 mm spherically focused transducers with 
center frequencies 5 MHz (Panametrics, Inc., Waltham, MA) was used for in vitro 
acoustic testing. [9, 56] A transducer does not emit at a single frequency, but at a broad 
range of frequencies. The difference between the highest and the lowest frequency 
emitted from the transducer is known as the bandwidth. The -6 dB bandwidth of the 
transducers was 92%. The transducer was inserted in a water bath filled with deionized 
water, (37C) and focused through transparent poly-acrylic window of a custom-made 
sample vessel.  A pulser/receiver (model 5072 PR, Panametrics, Inc., Waltham, MA) was 
used to pulse the transducers at a pulse repetition frequency (PRF) of 100Hz. The 
received signals were amplified to 40 dB and fed to the digital oscilloscope (Lecroy 
9350A, Lecroy, Chestnut Ridge, NY).  Data acquisition and processing was done using 
LabView 7 (National Instruments, Austin, TX, USA), which the programming was 
developed in our lab. Backscattering enhancement was measured as a function of UCA 
dosage and used to gauge the agent’s ability to provide enhancement. Enhancement in dB 
is defined as: [5] 
               
            
          
     Eq3.1 
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where ΣE is backscattering enhancement, SUCA(t) is the rms readings of 60 readings with 
UCA, and S0(t) is the rms readings of 60 readings prior to UCA injection. The bubbles 
were added into the sample chamber using an automatic pipette, and stirred with a 
magnetic stirrer throughout the readings.  The reference (PBS) is taken as an average of 
six values.  Readings with buffer alone indicate that this method does not introduce 
unwanted air bubbles into the sample chamber.  Enhancement and attenuation were 
calculated as a function of dose and time. 
 
 
Figure 3.1 A schematic of in vitro acoustic set up for testing ultrasound enhancement and stability of UCA 
[56] 
 
 There are two curves which may be constructed from the acoustic set up. First, the 
enhancement curve shows the echogenicity (dB of impinging sound that is reflected back 
to the transducer) of the bubbles as a function of dose. For each dose, the diluted sample 
of the bubbles from the size distribution measurement was added into 50 ml of 37
o
C PBS 
in the custom-made vessel then calculated and reported in the unit of l of the original 
concentration of bubbles per liter of PBS (l/L). All of the dose response results are 
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reported on fresh samples, and are not cumulative. Second, the stability curve shows the 
testing of the stability of the bubbles over time, under constant insonation. A dose on the 
linear rise of enhancement response curve must be chosen to conduct an accurate stability 
measurement. 
 
3.2.3.3 Scanning Electron Microscopy of UCA 
The morphology of the bubbles shell was imaged using an environmental 
scanning electron microscope (SEM) (FEI XL30, Hillsboro, OR). The bubble solution 
was dropped on to a stub and allowed to dry in cold temperature (4
o
C).  The dry bubble 
was then sputter coated with platinum-palladium for 40 seconds using a Denton Desk-II 
sputtering system (Denton Corp, NJ.) prior to imaging. Images were taken at varying 
magnifications at an accelerating voltage of 5 kV to avoid shell melt down. All SEM 
imaging and sample preparation was done at the Drexel University Materials 
Characterization Facility with assistance from Lauren Jablonowski. 
 
3.2.3.4 Turbidity Measurement for the Amount of Fabricated Nanobubbles 
 Because no direct measurement of the numbers per ml of fabricated nanobubbles 
was possible, a turbidity measurement was used. The more turbidity, the greater the 
amount of nanobubbles in the solution. The turbidity was measured by the absorbance at 
a wavelength of 610 nm and the value was reported as a relative value compare with the 
turbidity of the nanobubbles fabricated by the standard conditions. The amount of 5 L of 
the bubble solution was diluted with 195 L of cold (4oC) PBS in Non-sterile 
Polystyrene, Flat bottom, medium binding costar 96 well corning flat transparent plates 
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(Corning, NY). The absorbance was measured by Tecan infinite M 200 (Research 
Triangle Park, NC) instrument.  
 
3.2.3.5 Quantitative Measurement Amount of Paclitaxel by HPLC 
The amount of Paclitaxel loaded into the UCA was analyzed by the High 
Performance Liquid Chromatography (HPLC). The loaded Paclitaxel was extracted 
before the HPLC analysis. The equal volume 2.5 ml of Paclitaxel loaded bubbles and 
Ethyl Acetate were added into a 50 ml centrifugal tube. The mixture was then mixed by 
vortex mixing for 1 min, then centrifuged using a Beckman Coulter AllegraTM 21 
centrifuge with relative centrifugal force at 8528 g for 15 min. After the centrifugation, 
1.5 ml of the upper layer of Ethyl Acetate was taken, added to a glass bottle, and then 
evaporated in the fume hood. The extracted Paclitaxel was dissolved by adding 1.5 ml 
Acetonitrile. To make sure that Paclitaxel was completely dissolved in Acetonitrile, the 
glass bottle was sealed with parafilm, then shaken for 24 hours. The solution was passed 
through a 0.2 m syringe filtered before HPLC analysis. 
The Waters HPLC system (Waters Corporation, Milford, MA) was used for 
Paclitaxel concentration analysis with a reverse phase Inertsil ® ODS Column (250mm x 
4.6mm, 5m particle size, GL Science). The mobile phase was 60% Acetonitrile HPLC 
Grade to 40% 0.2 m filtered DI water at the flow rate of 1 ml/min. The column effluent 
was detected with UV detection at 227 nm. [50, 57-59]  
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3.2.4 In vivo Tumor Imaging  
3.2.4.1 Tumor Imaging 
The tumors in this study were 9L gliomas which were implanted by tying tumor 
pieces to the epigastric vein in Fisher 344 rats (Charles River Laboratories, Wilmington, 
MA). The tumors were imaged after growing to 10 to 20 mm in at least one dimension 
(approximately 3 to 8 weeks). General anesthesia was induced and maintained with 
isoflurane and oxygen in each rat, and the hair coat overlaying the tumor was removed by 
clipping and by the application of a depilatory cream. The tumors were imaged with 
broadband high-frequency ultrasound transducer at 7 to 15 MHz (Phillips ALT 5000; 
Phillips Ultrasound, Bothell, WA), which was mounted on a stand and fixed in a position 
aligned along the longest axis of the tumor. The ultrasound contrast agents were injected 
via a 26-gauge tail-vein catheter. Because the rat weight was around 250 g and the 
desired dose of the agents was 0.1 ml/kg, the agents were diluted four times before the 
injection of 0.1 ml of diluted agents.  
 There were two modes of imaging in this study, power Doppler and -projection. 
For a short time before, and then after the injection, the images were immediately 
acquired. The depth and field of view for each mouse was adjusted such that the tumor 
occupied the maximum area in the image. To minimize bubble destruction and to ensure 
high-quality images, the power Doppler was performed at an MI of 0.8, and the 
ultrasound scanner was externally gated at 0.5 frame/s. -projection images were 
constructed from gray-scale images to demonstrate tumor perfusion. All images were 
recorded on videotape and digitized for analysis of a percentage area of flow (PAF), 
which was equal to the percentage of the area of interest covered by the agent. 
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3.2.4.2 Image Analysis 
The data set consisted of images acquired before and after contrast injections. For 
the power Doppler imaging, a region representing the tumor was outlined in the pre-
contrast image and superimposed on the post-contrast images. A lookup table for the 
color levels was constructed by using the color palette on the Doppler scans. The color 
lookup table was used to identify colored pixels within the tumor. The percentage area of 
flow for power Doppler (PAFD) for each power Doppler image was determined by the 
percentage ratio of pixels enhanced by the contrast agent to the total number of pixels in 
the tumor cross-section. [60] 
 For -projection analysis, B-mode images of the data set were used. A region 
representing the tumor was outlined in the first pre-contrast image of the data set. 
Sequential projection images of the tumor region were reconstructed from the serial 
contrast-enhanced images by tracing the running maximum change in enhancement. A 
threshold gray-level difference was applied to the area enhanced by the inflow of contrast 
agent from the surrounding tissue. In summary, the procedure consisted of increasing the 
gray-level difference stepwise until the -projection showed the expected absence of 
enhancement. This approach mapped the pixels of blood vessels that were enhanced by 
contrast agent. For each image in the time series of the projection images, the percentage 
area of flow for -projection (PAF) was determined by taking the percentage ratio of 
pixels enhanced by contrast agent to the total number of pixels in the cross-section. [60] 
 The PAF was plotted with time and various parameters were compared between 
the two agents corresponding to the plotting (Figure 3.2). A first-pass kinetics gamma-
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variate function was used to calculate the perfusion ratio of both agents. [61, 62] The 
tumor perfusion calculation details are described in appendix B. 
 
 
Figure 3.2 Example of regions utilized in the percent area plot of Power Doppler and -projection 
 
3.2.5 Statistical Analysis 
 The results were shown as means with the error bars displayed as standard error 
about the mean (SEAM). Statistical analyses were performed using SPSS version 19 
(IBM, USA). The parameters were compared by a paired-samples two-tailed student t 
test. The level of significance was set to p<0.05 
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4. RESULTS AND DISCUSSION 
 
4.1 A New Model for the Gas Bubbles Stabilized by Surfactants 
The microbubbles stabilized by surfactant had been developed in our lab with an 
extensive study on mixing Span 60 and Tween 80 at the total surfactant concentration at 
85.1mM and the molar percentage of Span 60 to Tween 80 at 80:20 in 1X PBS with the 
addition of 0.51M of NaCl. This first generation agent is named ST68. 
Octafluoropropane gas yielded the best stability under ultrasound compared with Sulfur 
Hexafluoride and air. [6] ST44 consisting of Span 40 Tween 40 has also been prepared 
and studied. [6, 63] 
It has been observed that stable microbubbles can be formed only with a solid 
Span, i.e. Span 40 and Span 60, mixed with Tween. Neither the mixture of Span 80, a 
liquid form, with Tween nor Tween alone purged with PFC gas produced stable 
microbubbles, an observation in agreement with the study of Singhal who used air. [4] 
For this reason, the potential exists that the stability of the mixed surfactant gas bubbles 
can be modeled as solid particle-stabilized bubbles, not a mixture of dissolved 
surfactants. 
  
4.1.1 Differences between Surfactant Stabilized Foam and Particles-stabilized Foam 
In order to see the effect of Span and Tween ratios on the mixed surfactant 
system, mixtures of Span 60 and Tween 80, with a total initial concentration of 85.1 mM, 
were produced in the molar ratios of  20:80, 40:60, 60:40, and 80:20 Span:Tween. After 
autoclaving and cooling down to room temperature with constant stirring, the solutions of 
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pure Tween and at low molar percentages of Span and Tween mixtures (i.e. 10:90 and 
20:80) were clear compared with solution using higher percentages (e.g. higher than 
30:80), which had a milky appearance. (Figure 4.1) Size analysis of the pure Tween 80 
and a low percentage of Span 60 and Tween 80 solutions all showed exactly the same 
size distribution (mean diameter of between 8-10 nm), which is in the micelle range, 
compared with the mean diameter of higher percentages of Span 60 and Tween 80 that 
produced particles with mean diameters close to 60 nm (data not shown). In the case of 
low Span and Tween percentages, we hypothesize that the Tween in the mixture has 
increased the solubility of Span by formation of mixed micelles. This scenario agrees 
with a study by Eiser et al. [22], which showed increasing solubilization of a hydrophobic 
component (e.g. fat particles) in the presence of a water-soluble surfactant. In the case of 
the high Span 60 and Tween 80 ratios, we surmise that there was not enough Tween 80 to 
form mixed micelles with Span 60, and Tween 80 adsorbed onto the Span 60 particles, 
stabilizing the Span 60 particles while the solution cooled down to room temperature 
after the sterilization. In this way, small particles of Span 60 were formed by preventing 
the aggregation of Span 60 particles, and the solutions appeared cloudy. For the cooling 
of solutions of pure Span 60, the particles agglomerated and precipitated out, which can 
be seen by the naked eye. 
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Figure 4.1: The solution of mixture of Span 60 and Tween 80, the initial concentration of 85.1 mM, 
in the molar percentage of (i) 20:80, (ii) 40:60, (iii) 60:40,  
and (iv) 80:20, which is a standard ratio for ST68 
 
The hypothesis of the bubbles stabilized by the particles of Span with Tween also 
can be investigated by observing the dried foams (Figure 4.2). The dry foams can be seen 
in test tubes for pure Span 60 and the mixture of Span 60 and Tween 80 at molar 
percentage of 80:20 but not for pure Tween 80 and the mixture of Span 60 and Tween 80 
at a molar percentage of 20:80. These results resemble those in the study of Zhang et al. 
[23], which describes this unique characteristic of dried foam resulting from particle-
stabilized foam. 
i  ii  iii  iv 
34 
 
   
(a)                                                               (b) 
Figure 4.2: a) Foam and bubble of pure Span 60, mixture of Span 60 and Tween 80 at 80:20 and 20:80 and 
pure Tween 80, respectively, in test tube after sonication. b) Dry foam of pure surfactant and the mixtures  
 
4.1.2 The Effect of Particle Size on the Stability of Microbubbles 
 It has been observed by Fujii et al. that the particle size affects the stability of the 
resulting particle-stabilized foam. [17]   To explore this possibility on ST68, we followed 
up on an observation that was made during fabrication, that the particles are formed 
during the cool down period after autoclaving. 
 The constant amount of 2 m mole of Span 60 was mixed with the different 
amount of Tween 80 at 0.1, 0.5 and 1 m mole in 50 ml PBS with 1.5 g of NaCl to 
determine if the surfactant ratio had any effect on particle size. The particle sizes after 
autoclave and cool down to room temperature with constant stirring are shown in Figure 
4.3. The results showed that the particle size was smaller when the amount of Tween 80 
increased with the same amount Span 60.  
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Figure 4.3: Particle size after autoclave and cool down to room temperature of the mixture of 2m mole 
Span 60 with different amount of Tween 80 at 0.1, 0.5 and 1 m mole in 50 ml PBS 
 
ST68 agent was prepared with these samples and the mean diameters of the 
resulting bubbles from the mixtures are shown in Figure 4.4. There is no statistically 
significant difference when mixing the same amount of Span 60 at 2 m mole with 
different amount of Tween 80 at 0.1, 0.5 and 1 m mole in 50 ml PBS. The mean diameter 
of the bubbles was close to 2 m. It should be noted that for the mixture of Tween 80 at 
0.1 m mole, which gave the largest particle size with mean diameters close to 100 nm, 
there was the smallest yield of microbubbles, less than 0.5 ml after collecting the middle 
layer at the third wash compared with 5-10 ml for other particle sizes. Further decreasing 
the Tween 80 lower than 0.1 m mole, which should have lead to the bigger particle, was 
not a suitable condition to fabricate the microbubbles for contrast agent because the size 
of the bubbles were bigger than 8 m after the third wash. 
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Figure 4.4: Mean diameter of the bubbles fabricated from the mixture of 2m mole Span 60 with different 
amount of Tween 80 at 0.1, 0.5 and 1 m mole in 50 ml PBS (n=3, error bar=SEAM). 
 
 All of the agents fabricated from the mixtures gave a very good acoustic 
enhancement (Figure 4.5). The enhancement ranged between 25 dB to 30 dB. There was 
no statistically significant difference for maximum enhancement between these 
microbubbles.  However, the enhancement response curve of the microbubbles that were 
fabricated from 0.1 m mole of Tween 80 was different from the other two curves, in 
which it is taking a lot of agent to reach maximum enhancement. 
The in vitro stability under ultrasound of the agents is shown in Figure 4.6. The 
microbubbles fabricated from 0.1 m mole of Tween 80 were the most stable with the half 
life of 18.42 min, compared with 7.41 and 6.02 min for 0.5 and 1 m mole of Tween 80, 
respectively. This half life of microbubbles fabricated from 0.1 m mole of Tween 80 was 
statistically significant different from microbubbles fabricated from 0.5 m mole (p=0.001, 
n=3) and 1 m mole (p=0.001, n=3) of Tween 80. There was no statistically significant 
difference from microbubbles fabricated from 0.5 m mole and 1 m mole of Tween 80. 
These stability results showed that the stability of the microbubbles related to the size of 
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the particles. The bigger the particles, the more stable were the microbubbles. This 
stability of the bubbles can be explained by the energy to remove the particles from the 
interface (equation 2.4). [34] When the bubbles are exposed to the ultrasound, they will 
expand and contract due to compression and rarefaction of the sound waves. When the 
bubbles contract, the Laplace pressure increases (equation 2.3). This pressure can force 
the particle from the interface into the solution and make the bubbles unstable. From the 
equation 2.4, the energy required to remove the particles is higher when the particle is 
bigger. This could explain why the microbubbles fabricated from 0.1 m mole of Tween 
80, which consists of the biggest particle, is the most stable compared with other two 
conditions, one of them is the same ratio of 80:20 (2 m mole Span 60 to 0.5 m mole of 
Tween 80). These results agree with Fujii et al., which showed that the stability of the 
bubble is depended on particle size.  
 
 
Figure 4.5: In vitro ultrasound enhancement of the bubble fabricated from the mixture of 2m mole Span 60 
with different amount of Tween 80 at 0.1, 0.5 and 1 m mole in 50 ml PBS (n=3, error bar=SEAM). 
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 Figure 4.6: In vitro stability of the bubble fabricated from the mixture of 2m mole Span 60 with different 
amount of Tween 80 at 0.1, 0.5 and 1 m mole in 50 ml PBS (n=3, error bar=SEAM). 
 
4.2 Development and Characterization of a New Microbubble Formulation 
 A newly develop agent was fabricated by directly replacing Tween 80 with 
TPGS.  TPGS was selected for study because, like Tween, it has a restively bulky head 
group with attached polyoxyethylene -(CH2CH2O)- groups and a hydrophobic tail  
(Figure 2.9).  It is also well known as a pharmaceutical ingredient, which enhances the 
absorption, bioavailability and effectiveness of bioactive compounds. TPGS was also 
chosen because we wanted to use these agents as drug carriers for the ultimate goal of 
this study, and there are many studies [53-55, 64-66] which show TPGS increasing the 
amount of drug encapsulation. This new agent was named SE61.  
 Mean diameter of the new and original ST68 agents are shown in Table 4.1 with 
SE61 having a slightly smaller diameter than ST68. However, there is no statistical 
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bubble population was smaller than 8 m, which is ideal for the agent to pass the 
capillary beds.  
 
Table 4.1 Mean diameter of ST68 and SE61 
Agents Mean diameter (m) 
ST68 1.88±0.16 
SE61 1.31±0.20 
 
 The acoustic properties of SE61 compared ST68 are shown in Figure 4.7. SE61 
had a statistically significant (p = 0.011, n=3) higher in vitro maximum enhancement than 
ST68 (Figure 4.3a). The maximum enhancement of SE61 was 30.22±0.74 dB and it was 
22.16±0.70 dB for ST68. However, it should be noted that ST68 gave a maximum 
enhancement at a lower dose at 32 l/L compared with 120 l/L for SE61, suggesting 
that it is more concentrated sample.  
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(a) 
 
(b) 
Figure 4.7: In vitro ultrasound enhancement (a) and stability (b) of ST68 and SE61 at 37
o
C  
(n=3, error bar=SEAM). 
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SE61 was also statically significant (p = 0.023, n=3) and more stable under 
ultrasound than ST61 (Figure 4.3b). The half life of SE61 was 16.45±1.56 min compared 
with 5.20±0.20 min for ST68.   
 
4.2.1 The Morphology of the Microbubbles  
 A light microscope and SEM of SE61 are shown in Figure 4.8 and Figure 4.9, 
respectively. The light microscope assured that the population of the agent was 
comprised of bubbles smaller than 8 m. However, the morphology of the bubble could 
not clearly be seen under the light microscope due to the limitation of the light 
microscope. 
 
 
Figure 4.8: SE61 under light microscopy. The numerous small bubbles appearing as dark points in the 
background Bar = 10 m  
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(a) 
 
(b) 
Figure 4.9: SEM of SE61. The bubble was Pd/Pt sputter coating for 40 seconds. The higher resolution of 
the yellow square area in Figure (a) is shown in Figure (b) 
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 The sample of SE61 was diluted and dried on the stub in 4
o
C before imaging by 
SEM. The SEM showed that SE61 fabricated by the standard procedure consists of the 
micron-sized and nano-sized bubbles. During preparation the bubbles in the SE61 
mixture took a very long time to rise, which indicated to us that the sample contained a 
large number of nano bubbles which due to their lower buoyancy, took far longer to rise 
than the micron sized bubbles. The SEM gave the first positive evidence that the 
nanobubbles could be fabricated by the standard procedure and suggested the need for 
further study to find a method to increase the nanobubble population by modifying the 
standard procedure. 
The SEM, however, did not show us that the bubbles shell contains particles as 
hoped. It showed the bubbles had smooth surfaces. This might be because the particles 
that stabilized the bubbles were too small, ranging from 50 nm to around 100 nm, and 
could not be clearly seen after the sputter coating for SEM. Further studies on increasing 
the size of particles to support the particle stabilized model were conducted.    
 
4.2.2 The Effect of the Method of Making Particles and of Different Surfactant on 
the Stability of Microbubbles 
 The SEM images of the bubbles from previous studies could not confirm the 
existence of particles in the stabilized bubbles due to the possibility that the particles are 
too small to be detected after the sputter coating and do not show up when imaged by the 
SEM. In the original study, there was another way to prepare the mixture before the 
sonication. [4] Span 60 can be ground into smaller particles in a pestle and mortar with a 
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small amount of PBS and NaCl crystals before adding another surfactant. The mixture 
was then stirred without heating.  
 Dynamic light scattering of the particles of ground Span 60 mixed with TPGS is 
shown in Figure 4.10. The mean diameter of 380 nm of the majority of the particles, 
which was 87% smaller than 530nm, was mixed with big particles. The particles can be 
seen in the SEM imaging, which shows that most of the particles were smaller than 500 
nm (Figure 4.11). The SEM imaging of the microbubbles fabricated from this mixture is 
shown in Figure 4.12. It can be seen that upon drying, particles are still visible. Certain 
areas appear with particles grouped together in spherical arrangements. 
 
 
Figure 4.10: Particle distribution of ground Span 60 mixed with TPGS 
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(a) 
 
(b) 
Figure 4.11: SEM imaging of ground Span 60 mixed with TPGS. Higher magnification of the square in 
picture (a) is shown in picture (b) 
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Figure 4.12: SEM imaging of the bubble fabricated from ground Span 60 mixed with TPGS. The arrows 
are the possible examples of the microbubbles that stabilized by particles. 
 
 Further study was conducted to compare: i) the effect of Tween 80 and TPGS 
adsorbed onto ground Span 60 particle and ii) for TPGS, a comparison of bubble 
properties using either the ground or heating method of fabrication.  
 The microbubbles with diameter mostly in a range of 2-3 m could be fabricated 
from the mixture of Span 60 to Tween 80 and TPGS between the molar ratios of 1:0.125 
to 1:1, including ground Span 60 without another surfactant (Figure 4.13). It should be 
noted that the microbubbles could not be fabricated from heated Span 60 alone. There 
was no statistically significant difference in the size of microbubbles among all 
conditions. 
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Figure 4.13: Size of microbubble fabricated from ground Span 60 with Tween 80 (ground ST68) and 
TPGS (ground SE61) and heated Span 60 with TPGS (heated SE61) (n=3, error bar=SEAM) 
 
 The amount of microbubbles fabricated from all conditions were recorded and 
shown in Figure 4.14. For the ground fabrication method, there was no statistically 
significant difference between ST68 and SE61 at any given surfactant ratio. The amount 
of microbubbles was at the highest at the ratio of 1:0.25 (molar percent ratio of 80:20) for 
both ST68 and SE61. There was no statistically significant difference between the ratio of 
1:0.125, 1:0.25 and 100% Span 60, but there was statistically significant difference 
between the ratio of 1.0.25 and 1:0.5 (p=0.009 for ST68 and p=0.004 for SE61, n=3).  
 These results show the same trend as the previous study, in which the highest 
yield was when the ratio of Span 60 and Tween 80 was in between 60:40 and 80:20. 
Binks et al. [21] showed that at very low surfactant concentration of the adsorbed 
surfactant (compared to our conditions that the ratio of Span 60 to Tween 80 or TPGS are 
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particles to produce foam, is dependent on the partially coated particles due to the lack of 
availability of free surfactants. This is may be explain why there is not statistical 
significant among 100% ground Span 60  and the ratio of 1:0.125 and 1:0.25 for ground 
Span 60 with Tween 80 and TPGS. However, at higher concentration of the adsorbed 
surfactant, there are more free surfactants in the solution. We know that the bubbles that 
are stabilized by free surfactant, i.e. Tween or TPGS alone, are bigger than 8 m. This 
reason can explain why the yield of microbubbles was less at the ratio of 1:0.5 and 1:1. 
 
 
Figure 4.14: Amount of microbubble fabricated ground Span 60 with Tween 80 (ground ST68) and TPGS 
(ground SE61) and heated Span 60 with TPGS (heated SE61) (n=3, error bar=SEAM) 
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ratio of 1.0.25 and 1:0.5 (p=0.021 for n=3). There was no statistically significant 
difference for SE61 fabricated by the ground or heated methods at any given surfactant 
ratio. 
 The difference in yield obtained by the heating method can be explained by the 
size of the particles. Fujii et al. [17] showed that at the same surface morphology of the 
particle, size of the bubble is depended on the size of particles. The less mean diameter of 
the particles, the smaller mean diameter of the bubbles. However, if the particles are too 
small, these particle are efficient at preventing bubble coalescence during foaming. We 
know from section 4.1.2 that the particles are smaller when the ratio of Span 60 and 
Tween 80 is higher, this should explain why it is higher yield at the ratio 1:0.25 than 
1:0.125. The mean size of particle at 1:0.125 and 1:0.25 were around 60-100 nm 
compared with 20-30 nm at the ratio of 1:0.5 and 1:1. It is possible that the bubbles from 
high ratio may not stable enough to survive three time washing steps in separation funnel. 
 The in vitro maximum enhancement of microbubbles is shown in Figure 4.15.  
There was no statistically significant difference for the maximum enhancement for all 
conditions, except for the 100% Span 60 compared with all other conditions. 
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Figure 4.15: In vitro maximum enhancement of microbubble fabricated from ground Span 60  
with Tween 80 (ground ST68) and TPGS (ground SE61) and heated Span 60 with TPGS (heated SE61)  
(n=3, error bar=SEAM) 
 
 The in vitro half life of microbubbles under ultrasound is shown in Figure 4.16.  
There was no statistically significant difference for the half life for all conditions, except 
for ground SE61 at the ratio of 1:0.25 to 1:0.5 (p=0.018, n=3) and 1:0.25 to 1:1 (p=0.037, 
n=3). It should be noted that for the heated SE61, the half life showed the same trend as 
ST68 in the study in section 4.1.4, which was the stability of the microbubbles under 
ultrasound decreased when increasing the molar ratio of Span 60 to another surfactant 
component. 
  As mentioned before with Binks et al. work [21], it is possible that there is a 
different mechanism between the lower ratio (1:0.125 and 1:0.25) and the higher ratio 
(1:0.5 and 1:1). This could explain why there is a statistically significant difference 
between the lower ratio and higher ratio. 
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Figure 4.16: : In vitro half life of microbubble fabricated from ground Span 60 with Tween 80 (ground 
ST68) and TPGS (ground SE61) and heated Span 60 with TPGS (heated SE61)  (n=3, error bar=SEAM) 
   
4.2.3 Conclusion on Particle Stabilized Model for ST68 and SE61 
 The microbubbles with mean diameter around 2 m can be fabricated by mixing 
Span 60 with Tween 80 (named ST68) and Span 60 with TPGS (named SE61). The size 
of the particles could be controlled by the ratio of the surfactant. The SEM imaging of 
microbubbles fabricated by the particle size in a range of 200-500nm shows that these 
microbubbles were dry to a collection of particles. The size of particles also dictates the 
stability of microbubbles under ultrasound, which can be explained by the particle 
stabilized foam theory. 
 
 
 
0.00 
2.00 
4.00 
6.00 
8.00 
10.00 
12.00 
14.00 
100% Span60 1:0.125 1:0.25 1:0.5 1:1 
H
a
lf
 L
if
e 
(m
in
) 
Ratio of Span 60 to Tween80 and TPGS 
100% Span60 
Ground ST68 
Ground SE61 
Heated SE61 
52 
 
4.3 Investigations into the Nano-sized Contrast Agent  
During the investigation of the potential of TPGS to substitute for Tween 80, it 
was noted that the bottom layer while doing the washing step using the heated SE61, was 
more turbid compared with ST68 when following the standard procedure. In addition, it 
took far longer for the layer to clear to collection of the bubbles in the middle layer due to 
buoyancy. This should suggest it was possible that there were more nanobubbles 
produced when alternating the surfactant component from Tween 80 to TPGS.    
 
4.3.1 The Properties of the Bottom Layer in the Third Wash of SE61 
 First, it should be confirmed that the increased turbidity of the bottom layer was 
due to an increased number of nanobubbles, not the unused surfactants. These 
nanobubbles can be collected by following the standard procedure (appendix A.2) except 
at the end of the third washing step, the very bottom layer containing settled Span 
particles, 50-75 ml, was discarded. Unused surfactant particles should be discarded in this 
step. After that, 10 ml of solution just underneath the middle layer of microbubbles was 
collected for further analysis. This layer should contain nano bubbles that were rising at a 
slower rate than the micro bubbles. 
  The number size distributions of the collected solution (in green color) compare 
with the particle before sonication (in red color) are shown in Figure 4.17. The size 
distribution showed that the majority of nanobubbles were mixed with a small amount of 
microbubbles. More than 95% of the bubbles were smaller than 615 nm, with a mean 
diameter of 286 nm, compared with 46 nm for the particles. 
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 The acoustic properties were tested to ensure that the population with mean 
diameter of 286 nm was nanobubbles not unused surfactant particles since the unused 
surfactant would not give a high ultrasound enhancement. 
 
 
Figure 4.17: Number size distribution of 10ml of the solution just underneath the middle layer of 
microbubbles 
 
 From Figure 4.18a, the maximum enhancement of these nanobubbles was 
21.63±1.36 dB. The in vitro stability (Figure 4.19b) was very low. The nanobubbles had 
the half life only 1.75±0.24 min compared with 16.45±1.56 min for SE61 microbubbles. 
This suggests that these results are dominated by nano bubbles not co-collected 
microbubbles. The difference in stability between the nanobubble and microbubbles 
could be explained by the difference in Laplace pressure. Since the nanobubbles would 
have higher Laplace pressure, it would be less stable compared with the microbubbles. 
These nanobubbles of SE61 were named nSE61. 
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(a) 
 
(b) 
Figure 4.18: In vitro enhancement (a) and stability (b) of nanobubble SE61 fabricated standard procedure 
but collected 10ml just underneath the middle layer of microbubbles  (n=3, error bar=SEAM) 
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4.3.2 The Effect of Total Surfactant Concentration on Nanobubble Population 
 The further study was to increase the nanobubble population. The first parameter 
investigated in this study was the effect of total surfactant concentration on size 
distribution. Dickinson et al. [16] showed that the concentration of the particles has some 
effect to the bubble size and its stability. The SOP in appendix A.2 was followed for 
separation of nano bubbles after the third wash, except that the amount of starting 
surfactant was varied.  Figure 4.19 shows the mean diameter of nanobubbles when the 
total concentration of surfactant is varied at a percentage ratio of Span:TPGS constant at 
80:20. The standard total concentration was 85.1 mM. This study compared the standard 
total concentration by decreasing the total concentration to 50 mM and increasing the 
total concentration to 100 mM. The mean diameter of nanobubbles was not statistically 
significant different in all conditions. 
 
 
Figure 4.19: Bubble mean diameter when vary the total surfactant concentration at constant Span:TPGS 
ratio (n=3, error bar=SEAM) 
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Because there was no direct measurement of the number of nanobubbles, the 
amounts of fabricated nanobubbles were compared by means of turbidity measurement. 
The turbidity of the standard condition was set to one and other measurements were 
normalized by comparing them to this value. The results of the measurement are shown 
in Figure 4.20. The amount of nanobubble was highest at the standard total concentration 
of 85.1 mM. Decreasing and increasing resulted in decreased turbidity, which means a 
less fabricated nanobubbles population. Both decreases were statistically significant when 
compared with the standard conditions (p=0.031 for 50 mM and p=0.002 for 100 mM). 
This molar ratio and total molar concentration was found to be optimal for microbubble 
preparation in ST68 as well. [3] 
 
 
Figure 4.20: Relative turbidity when vary the total surfactant concentration (n=3, error bar=SEAM) 
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concentration lead to less stability. Since the nanobubbles has to be in the separation 
fennel at least three hours for three times in washing step, the less stable bubbles may not 
survive in this step. However, when increasing the total concentration, the nano 
population also decreased. This can be explained by size of particles. [17] The mean size 
particles of total concentration of 100 mM was around 200 nm, compared with around  
60 nm for 85.1 mM. The relatively larger particle may produce larger bubbles, which was 
rise to the middle layer faster, resulting in decreasing in nanobubbles population.  
  
4.3.3 The Effect of Sonication Power on Nanobubble Population 
 The next parameter in this study was sonication power. Brotchie et al. [67] 
showed that the power of sonication had an effect to the mean bubble size.  Figure 4.21 
shows the mean diameter of nanobubbles when sonication power was varied. The 
standard sonication power was 110 W. This study compared the standard sonication 
power by decreasing the sonication power to 80 W and increasing the sonication power to 
140 W (the maximum power available). The mean diameter of nanobubbles was not 
statistically significant different in all conditions. 
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Figure 4.21: Bubble mean diameter when vary the sonication power (n=3, error bar=SEAM) 
 
 The results of the turbidity measurement when varying the sonication power are 
shown in Figure 4.22. The amount of nanobubbles was again highest at the standard 
sonication power of 110W. This decrease and increase in sonication power resulted in a 
decrease in turbidity, which means a smaller fabricated nanobubbles population. Both 
decreasing and increasing, however, was not statistically significant when compared with 
the standard conditions. 
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Figure 4.22: Relative turbidity when vary the sonication power (n=3, error bar=SEAM) 
 
4.3.4 Conclusion on Nanobubbles 
 The nanobubbles nSE61 can be fabricated and collected separately from 
microbubbles if needed. These nanobubbles, however, gave less ultrasound enhancement 
and were less stable compared to microbubbles of SE61. There will be some benefit for 
less stability of nanobubbles under ultrasound because the nanobubbles will be used as 
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be less stable. By means of the turbidity measurement, the maximum amount of 
nanobubbles population was fabricated at the standard conditions. 
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4.4 In vivo Tumor Perfusion 
 Because a greater nanobubbles population of SE61 was successfully fabricated 
compared with ST68, specific aim 4 tested the hypothesis that among the two agents with 
different sized distributions, the agent with the smaller bubbles would be better in 
ultrasound imaging and tumor perfusion.  
 
4.4.1 ST68 and SE61 Size Distribution 
 The agents were fabricated in the same conditions as the total concentration of 
surfactants at 85.1 mM and the ratio of Span 60 to Tween 80 and Span 60 to TPGS at the 
percentage ratio of 80:20. The amount of 1.5 g of NaCl, which is amount according to the 
standard procedure of a previous study, was added into the mixture of surfactants in 50 
ml of PBS. Other studies have shown that the NaCl enhances the nano population, 
possibly due to charge stabilization since the bubbles can acquire a static negative charge 
during fabrication. [68] The mixture fabricated also followed the standard procedure. At 
the end of the third washing step, a middle layer was collected and mixed with cold PBS 
at the ratio of 1:1 for ST68. For SE61, the amount of 75 ml from the bottom layer was 
discarded after one hour at each washing step, and then the mixture of nano- and 
microbubbles was collected. 
 The number size distribution shows that ST68 is comprised of bubbles ranging 
from 955 nm to 2.67 m with a mean diameter of 1.63 m. For SE61, the size ranged 
from 342 nm to 900 nm with a mean diameter of 548 nm (Figure 4.23, ST68 in green and 
SE61 in red). This result confirmed the idea that the nanobubbles were produced more 
when changing from Tween 80 to TPGS. 
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Figure 4.23: Size distribution of ST68 and SE61 
 
4.4.2 In-vitro Ultrasound Enhancement and Stability Testing 
Both agents gave a good ultrasound enhancement in in-vitro testing. The 
maximum enhancement for ST68 was 23.61 ± 0.97 dB and 23.38 ± 0.98 dB for SE61 
(Figure 4.24a). Both agents also showed almost the same stability (Figure 4.24b). The 
half life of ST68 was 5.54 ± 0.43 min and 5.20 ± 0.20 min for SE61. There is no 
statistically significant difference between both agents in in-vitro ultrasound testing. 
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(a) 
 
(b) 
Figure 4.24 In vitro ultrasound enhancement (a) and stability (b) testing of ST68 and SE61  
(n=3, error bar=SEAM) 
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4.4.3 Tumor Perfusion Imaging 
 The Power-Doppler images for both agents are shown in Figure 4.25. Each time 
frame is marked at the time of injection (a), SE61 arrival time (b), ST68 arrival time (c), 
SE61 maximum coverage time (d), ST68 maximum coverage time (e), and time after 
maximum coverage for both agents (f). B-mode images for -projection are shown in 
Figure 4.26.  Each time frame is marked at time of injection (a), SE61 arrival time (b), 
SE61 maximum arrival time (c), ST68 arrival time (d), ST68 maximum arrival time (e), 
SE61 maximum coverage time (f), and ST68 maximum coverage time (g). The tumor 
vessel can be clearly seen during the wash-in phase in B-mode but is hard to see in 
Power-Doppler. 
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(a) 0, injection time 
 
 
(b) 3.5s, SE61 arrival time 
 
 
(c) 9.75s, ST68 arrival time 
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ST68 
SE61 
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(d) 13.75s, SE61 maximum coverage time 
 
 
(e) 14.75s, ST68 maximum coverage time 
 
 
(f) 17.75s, time at after maximum coverage of both agents 
Figure 4.25 Power Doppler Images of ST68 (left) and SE61 (right) at different time 
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(a) 0, injection time 
 
(b) 6.7s, SE61 arrival time 
 
(c) 7.53s, SE61 maximum arrival time 
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(d) 8.43s, ST68 arrival time 
 
(e) 9.51s, ST68 maximum arrival time 
 
(f) 19.4s, SE61 maximum coverage time 
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(g) 22.3s, ST68 maximum coverage time 
Figure 4.26 B-mode images for -projection of ST68 (left) and SE61 (right) at different time 
 
4.4.4 Tumor Data Analysis 
Data analyses for Power Doppler imaging are shown in Figure 4.27 and also 
summarized in Table 2.2. For the wash-in phase, SE61 reached the tumor earlier than 
ST68. Time to enhancement for SE61 was 6.50±0.88 seconds and 8.67±0.53 seconds for 
ST68 (p=0.036, n=6). However, in time to maximum coverage for both agents, there is 
no statistically significant difference (17.42±2.17 seconds for SE61 and 19.79±3.16 
seconds for ST68), (Figure 4.27a). For the wash-out phase, there is a statistically 
significant difference for early clearance between both agents. Time to 67% coverage for 
SE61 was 76.83±14.47 second and for ST68 was 54.46±10.77 seconds (p=0.023, n=6). 
Time to 50% coverage for SE61 and ST68 were 98.58 ± 15.26 and 76.83±14.47 second, 
respectively (p=0.038, n=6). However, there was no statistically significant difference for 
late clearance (time to 33% coverage for SE61 is 118.25 ± 15.02 seconds and 100.42 ± 
8.14 seconds for ST68 with p=0.057, n=6), (Figure 4.27b). It should be noted that all time 
to 67%, 50% and 33% coverage was time at maximum coverage to the time that the 
tumor coverage was at 67%, 50% and 33%, respectively. 
ST68 SE61 
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For Power-Doppler imaging, there is no statistically significant difference 
between both agents in maximum coverage and area under curve (AUC). (Figure 4.27c 
and 4.27e) In contrast the perfusion ratio (arbitrary units) calculated by a first-pass 
kinetics gamma-variate function shows that there is statistically significant difference 
between both agents (63.30 ± 5.45 for SE61 and 42.03 ± 6.54 for ST68 with p = 0.027, 
n=6). (Figure 4.27d) 
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(e) 
Figure 4.27 Quantitative analysis of Power Doppler imaging: (a) wash-in phase, (b) wash-out phase,  
(c) maximum area coverage, (d) tumor perfusion, and (e) area under curve (n=6, error bar=SEAM) 
 
Table 4.2 Summary of quantitative analysis of Power Doppler imaging * (p<0.05, n=6) 
Parameters ST68 SE61 
Wash-in Phase 
Time to Enhancement 8.67±0.53s 6.50±0.88 s* 
Time to Maximum Coverage 19.79±3.16s 17.42±2.17s 
Wash-out Phase 
Time to 67% Coverage 54.46±10.77s 76.83±14.47s* 
Time to 50% Coverage 76.83±14.47s 98.58 ± 15.26s* 
Time to 33% Coverage 100.42 ± 8.14s 118.25 ± 15.02s 
Percent Area Coverage 86.34 ± 4.45 80.96 ± 4.90 
Perfusion (Blood Flow) Ratio 42.03 ± 6.54 63.30 ± 5.45* 
Area under 
Curve 
Total 9284 ± 1287 7454 ± 572 
After Max Coverage 8436 ± 1404 6421 ± 445 
Gamma Function 5307 ± 1474 4746 ± 911 
Difference of Total and Gamma Function 3977 ± 1200 2708 ± 671 
7453.67 
6420.83 
4745.67 
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0 
2000 
4000 
6000 
8000 
10000 
12000 
Total AUC After max coverage Gamma Function AUC Total and Gamma 
AUC Difference 
ST68 
SE61 
72 
 
There was an improvement in tumor perfusion with the SE61 which contained a 
higher proportion of nanobubbles compared to ST68. Residence time in the tumor was 
also greater. It should be noted that the difference between SE61 and ST68 in the early 
clearance phase was more pronounced than the late clearance in the wash-out phase. This 
should support the hypothesis that the small bubbles can exit through the ‘leaky’ vessel 
making it harder to exit the tumor. The study in the last specific aim showed that the 
smaller the bubble, the less stable it is. This might explain why the early clearance is 
more pronounced than the latter clearance.  
Data analyses for -projection imaging are shown in Figure 4.28. All time to 
enhancement, time to maximum coverage, and maximum arrival time (which means the 
time for the maximum amount of the agent to enter the tumor) were statistically 
significant different between both agents. (Figure 4.28a) For the maximum coverage, 
however, there is not statistically significant difference between both agents, which was 
in agreement with Power-Doppler imaging. (Figure 4.28b) 
 
4.4.5 Conclusion on in vivo Tumor Perfusion 
Both agents gave excellent improvement in image contrast of the tumors. 
However, the choice of mode of imaging makes a difference in the details of the image. 
Both of our agents showed a visible vascular structure in the tumor in B-mode which is 
superior to Power Doppler image. The agent with the higher nano population entered the 
tumor faster, perfused better, and took a longer time to clear out. From these results, 
SE61 will be a good candidate for using as an ultrasound triggered drug carrier. 
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(a) 
 
(b) 
Figure 4.28 Quantitative analysis of Power Doppler imaging: (a) wash-in phase and (b) maximum area 
coverage, (d) tumor perfusion, and (e) area under curve (n=4, error bar=SEAM) 
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4.5 UCA as Carrier for Drug Delivery 
The next study was to investigate the potential of the bubbles to act as drug 
carriers. Because the shell of the bubble was comprised of a hydrophobic portion, the 
hypothesis that the hydrophobic drug can be intercalated into the bubbles shell was 
tested. First, Nile Red was chosen as a hydrophobic drug model because its fluorescent 
property depends on its surrounding hydrophobicity, a so-called solvatochromic probe. 
This should be proof of principle that the hydrophobic drug can be intercalated into the 
hydrophobic shell of the bubbles. Second, a highly hydrophobic drug, Paclitaxel, was 
used to intercalate into the bubbles. The quantitative analysis was conducted to measure 
the amount of the Paclitaxel that could be intercalated into the bubbles and hence 
determine if the concentration would be high enough to warrant future study on the 
effectiveness of Paclitaxel loaded drug to cancer cell lines and in vivo testing. 
 
4.5.1 Nile Red as a Hydrophobic Drug Model 
The agent ST68 was first chosen for drug carrier study of Nile Red loaded 
microbubbles, since this agent is the most well characterized in previous work. Nile Red 
was added into the solution after the autoclave step and then heated until the solution 
boiled for 3-5 min. At this point, the solution color changed from milky white to pink or 
red depending on the amount of Nile Red that was added. This is due to Nile Red 
becoming dissolved into micelles with a resultant changed color in the non polar 
environment of the micelle. The solution was then left to cool down to room temperature. 
Microbubbles were then made by sonication at 110 W for 3 min in the presence of PFC. 
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The qualitative analysis of Nile Red intercalated in the bubbles can be tested by 
the fluorescent property of Nile Red. As mentioned before, Nile Red is strongly quenched 
in aqueous media and will fluoresce depending on the polarity of its environment. As 
hypothesized, the Nile Red should be intercalated into the hydrophobic shell of the 
bubbles. If the bubbles are observed under the fluorescent microscopy, the glowing shell 
of the bubbles against the dark in the solution should be seen. The glowing bubble shell 
under florescent can be seen in Figure 4.29. This image confirms the hypothesis. 
 
 
Figure 4.29 ST68 with Nile Red under fluorescent microscope (=620nm) 
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4.5.2. Paclitaxel Loaded UCA 
The next goal of this study was try to intercalate Paclitaxel into the shell of the 
bubble. The amount of 10 mg of Paclitaxel was added into the solution after the 
sterilization step and then heated until the solution boiled for 30 min. The solution was 
then left to cool down to room temperature and follow the standard procedure for 
fabricating Paclitaxel loaded bubbles. 
Both Paclitaxel loaded agents still gave a good ultrasound enhancement and no 
statistically significant difference in in-vitro testing compared with the control. (Figure 
4.30a). Both Paclitaxel loaded agents show more stability when compared with the 
control but with no statistically significant difference (Figure 4.30b).  
The quantitative measurement for the amount of Paclitaxel was done by HPLC. A 
calibration curve by area under peak is shown in Figure 4.31. The linear regression shows 
a very good agreement with raw data (R
2
=0.9985) 
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(a) 
 
(b) 
Figure 4.30 In vitro ultrasound enhancement (a) and stability (b) testing of ST68 and SE61 
(n=3, error bar=SEAM) 
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Figture 4.31 A calibration curve of Paclitaxel by HPLC with mobile phase of Acetoniltrile:DI water at 
percentage ratio of 60:40 at 1 ml/min by UV detector at 227 nm 
 
 The amount of Paclitaxel intercalated into the SE61 and ST68 is shown in Figure 
4.32. The concentration of Paclitaxel in the solution was almost the same for both agents 
(3.79 g/ml for SE61 and 3.77 g/ml for ST68). This concentration was well above the 
suggested effective level of 0.043 g/ml [69, 70]. 
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Figure 4.32 Paclitaxel concentration intercalated in SE61 and ST68 by HPLC with mobile phase of 
Acetoniltrile:DI water at percentage ratio of 60:40 at 1 ml/min by UV detector at 227 nm  
(n=3, error bar=SEAM)  
 
4.5.3. Conclusion on UAC as Carrier for Drug Delivery 
 The hydrophobic drug can be intercalated into the microbubble shell. For 
Paclitaxel, the drug did not statistically alter the acoustic enhancement and the stability in 
vitro testing. For both agents, the amount of Paclitaxel loading was not different and the 
concentration was close to 100 times higher than the suggested effective concentration. 
[69, 70] The success of intercalating Paclitaxel into UCA can lead to further study of 
such alternative methods of cancer treatment by Paclitaxel with the goal of improving the 
efficiency of treatment and the reduction of undesirable side effects. 
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5. CONCLUSIONS AND FUTURE RECOMMENDATIONS 
 
5.1 Conclusions and Contribution to Science 
 The objectives of this study were to test a new model, particle stabilized foam, in 
a surfactant-based UCA, and to fabricate a greater nanobubbles population UCA and put 
them to the test that the agent can perfuse in a tumor better than the rich microbubbles 
UCA. Not only imaging capability of the agents was tested, but also the ability to act as 
drug carriers was investigated. 
 The new agent, SE61, was developed by replacing the Tween 80 component in 
ST68. The new agent gives better ultrasound enhancement and stability for in vitro 
testing. The stability of the agents under ultrasound is influenced by the size of particles 
that we used to make the bubbles. 
 Not only does it have better acoustic properties, the new agent SE61 is also 
comprised of more nanobubbles using the same conditions used to fabricated the ST68.  
 In vivo tumor imaging for the two agents was conducted. Both agents provided an 
excellent improvement in imaging of vascular structure in the tumor. The choice of mode 
of imaging, however, makes a difference in the details of the image. The further imaging 
analysis and calculation showed that SE61 perfuses better and take longer to clear out of 
the tumor, possible as a result of the larger nano population. 
 The ability of the agents to act as drug carriers was also tested. The results show 
that it was possible to intercalate the hydrophobic drug into the shell of the agents. The 
highly hydrophobic cancer treatment drug Paclitaxel can be loaded into the agent with 
higher than the recommended concentration for the minimum effective level. 
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 These results show the advance in tumor perfusion in ultrasound imaging. With 
the particle stabilized bubble model, this study can lead to an alternative way for advance 
drug delivery for cancer treatment. 
 
5.2 Future Recommendations 
 For each specific aim, further study can lead to improvement and better 
understanding.  
In specific aim 1, the contact angle of the particles between PBS and PFC should 
be measured. The measurement of contact angle may also help to explain the stability and 
size of the bubble. With the particle stabilized bubble model, it will be interesting to see 
if it possible to use drug particles to stabilized the bubble. Not only will this improve 
drug loading capacity, it also will be a new method for drug delivery. 
 For specific aim 2, Brotchie et al. found that one parameter that affected the size 
of the bubble when using a sonicator to form bubbles is the frequency of sonication. [69] 
It cannot be tested in this study because a sonicator that can change in frequency is not 
commercially available. 
 Finally, in specific aim 4, the results of this study show that it is possible to 
loading the drug into the agent. However, the effectiveness of drug loaded agent was not 
tested. In vitro and in vivo effectiveness should be further investigated. 
For a long term goal, the hypothesis that the drug loaded surfactant-based UCA 
with ultrasound will be more effective still has to be tested. It is also a room for 
improvements in terms of targeting imaging and drug delivery. The addition of targeting 
ligands may allow development of agents with a greater affinity for these improvements. 
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Appendix A: Standard Operating Procedures 
 
A.1 Procedure for Fabrication of ST68 Contrast Agent 
 The standard procedure in this study is modified from previous standard 
procedure with no grinding step before autoclave. 
1. 1.5g of sodium chloride, 1.48 g of Span 60, and 1ml of Tween 80 are added to 
50mL of PBS, with a stirrer bar. 
2. The beaker is covered with foil to which is attached a piece of autoclave tape and 
then stir. 
3. The mixture is slowly heated with continuous stirring to bring to a boiling, and 
dissolve the solid Span. 
4. The mixture is autoclaved with the stir bar in place for 35 min.    
5. The mixture is allowed to cool to room temperature while rapidly stirring so that 
the Span comes out of solution as fine particles. 
6. After the mixture has cooled to room temperature, it is prepared for sonication.  
(MAKE SURE TO REMOVE MAGNETIC STIRRER BAR) 
7. The beaker is placed in an ice bath. 
8.  gas of choice (usually PFC or 
SF6) gas until bubbles cover the solution before sonication. 
9. After it has been purged, the mixture is sonicated at between 110W for 3 minutes 
(Misonix Inc. CL4 tapped horn probe with 0.5” tip, Farmingdale, NY) with 
constant purging using a steady stream of gas of choice. 
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NOTE:  
1. When purging with gas, the tip that supplies the gas WILL be in the solution.  
When sonicating, the tip supplying the gas will NOT be in the solution, only the 
sonication probe will be submerged. 
2. During the sonication, the top of the beaker is covered with foil to trap the gas. 
10. One sterile separation funnels are set up in that cold room to cool to 4oC.   
11. The contents of the beaker are poured into the separation funnels.  
12. Wash three times with 50 ml PBS allowing 35 min of separation and discard the 
bottom layer.  
13. At the end of the third wash, a middle layer (microbubbles) is collected. 
14. The bubbles are either taken up into vacutainer tubes which are completely filled, 
or placed in glass vials, which are tightly capped only after the head space has 
been purged with the filling gas (usually PFC or SF6).  These vials are stored at 
4
o
C, characterized and used in 24 hr. 
 
A.2 Procedure for Fabrication of SE61 Contrast Agent 
 The standard procedure for standard SE61 is slightly different form ST68. 
1. 1.5g of sodium chloride, 1.464 g of Span 60, and 1.288 g of TPGS are added to 
50mL of PBS, with a stirrer bar. 
2. The beaker is covered with foil to which is attached a piece of autoclave tape and 
then stir. 
3. After TPGS all dissolve, the mixture is slowly heated with continuous stirring to 
bring to a boiling, and dissolve the solid Span. 
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4. The mixture is autoclaved with the stir bar in place for 35 min.    
5. The mixture is allowed to cool to room temperature while rapidly stirring so that 
the Span comes out of solution as fine particles. 
6. After the mixture has cooled to room temperature, it is prepared for sonication.   
7. The beaker is placed in an ice bath. 
8.  gas of choice (usually PFC or 
SF6) gas until bubbles cover the solution before sonication. 
9. After it has been purged, the mixture is sonicated at between 110W for 3 minutes 
with constant purging using a steady stream of gas of choice. 
For separate micron-sized and nano-sized SE61 
10. Two sterile separation funnels are set up in that cold room to cool to 4oC.  (Using 
a 125 ml separation funnel yields good results) 
11. The contents of the beaker are poured into one of the separation funnels (A), 
assisted by 50 ml cold PBS and the separation funnel is place in the fridge for one 
hour to allow for separation of the bubbles. 
11. After one hour the lower 25 ml of solution is discarded and the next 50-75 ml of 
the solution is transfer to the second cold separation funnel (B). 
At this stage separation funnel A contains the majority of micron sized bubbles 
and funnel B contains the majority of nano sized bubbles. 
 
 
 
 
93 
 
Funnel A. 
1) Wash twice with 50 ml PBS allowing one hour of separation and discard the 
bottom layer. At last wash, the middle layer containing predominantly micron 
sized bubbles is collected, and the lower portion is discarded. 
Funnel B 
1) Wash twice with 50 ml PBS allowing one hour of separation. Since there is no 
distinct layer for nanobubbles after the end of waiting period, 25ml of solution is 
discarded from the bottom of the separating funnel. The 10ml of nanobubbles is 
collected after the last discard.  
For mixed micron-sized and nano-sized SE61 
10. One sterile separation funnels are set up in that cold room to cool to 4oC.   
11. The contents of the beaker are poured into the separation funnels.  
12. Wash three times with 50 ml PBS allowing one hour of separation. For the first 
and second washed, 50-75 ml of solution is discarded from the bottom of the 
separating funnel if no distinct layer is seen. For the third washed, 75 ml of 
solution is discarded.  
15. A bottom layer (nanobubbles) and a middle layer (microbubbles) are collected all 
together. 
The bubbles are either taken up into vacutainer tubes which are completely filled, or 
placed in glass vials, which are tightly capped only after the head space has been purged 
with the filling gas (usually PFC or SF6).  These vials are stored at 4
o
C, characterized and 
used in 24 hr. 
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A.3 Procedures for in vitro Acoustic Characterization 
The amount of 0.2 ml of the bubble is diluted to 10 ml in volume metric flask that 
made up the volume with cold (4
o
C) of PBS. The following is the procedures for 
enhancement curve. 
 
1. Add 50 ml of 37oC membrane filtered 1X PBS (pH7.4) to the custom vessel with 
a stirrer bar.  
2. This vessel is placed into another cubical tank with 20 gallons of 37oC distilled 
water.  
3. The stirrer is adjusted to level 3 and continue to stir throughout the measurement. 
4. Create a new folder and subfolders for saving the results in the data folder  
5. Lab VIEW 7.1 ( National Instruments) software is used for acoustic testing  
6. Click on the run button and choose a directory path, which was created in the step 
4 to save the acquired data.  
7. First running baseline, in the sample name folder write Baseline and click on 
Make baseline for the acquisition, then click acquire.  
8. In the sample name type the dose of the bubble being injected. 
9. Add the required dose of the diluted bubble to the custom vessel then click 
acquire.  
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10. Each dose after the previous acquisition, clean and replace the 37oC PBS in the 
custom vessel. 
11. Repeat with increasing doses until shadowing effect is seen. begins to affect 
enhancement  
12. Export the data to the created folder and save them.  
13. All doses are calculate back to the original concentration and reported as l/L 
 
The following is the procedures for stability curve. 
1. Set number of time points to acquire 15 min of stability testing. 
2.  Click on the run button and choose a directory path, which was created to save 
the acquired data. 
3. Click on capture waveform on set time interval. 
4. Chose dose on the rise of enhancement curve and added this dose to the custom 
vessel filled 37
o
C PBS. 
5. Click acquire and export the data to the folder after 15 min.  
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A.4 Procedure for Size Distribution Measurement  
1. Crate data file and open it. 
2. Select measurement SOP by selecting Measure --> SOPs --> Size --> STXX then 
named the sample. 
3. Add 1ml of diluted bubble from acoustic testing into a low volume disposable 
sizing tapered cuvette, and then place the cuvette in the slot of the instrument. 
4. Click “Start” in protocol window. 
5. The measurement is taken three times with 15 second between each reading. The 
sample is gentle turn upside down and back again for 5 times between reading to 
ensure that the bubbles are not floating and accumulate at the top of the solution. 
 
 A.5 Procedure for Concentration Measurement by HPLC 
 Method Setup 
 The conditions for running HPLC will be setup and save for future use. The 
previous method that already created also can be modified. The instruments no need to 
turn on for the setup. 
1. Open Breeze Software, the click “View Method”, a top one on a left panel, and 
then choose LC for HPLC.  
2. For Pump Setting, set flow rate for pump A and B in Flow tab, indicate mobile 
phases used in Solvents tab, and temperature in Temperature Control tab (This 
temperature should be the same as column temperature. If the condition running at room 
temperature, 30
o
C is recommended to avoid the fluctuation of room temperature) 
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3. Set wavelength for UV detector. There are possible using two wavelengths 
simultaneously by checking Dual in Wavelength Mode.  Then set wavelength in Channel 
1 and 2 tab. 
4. Click File, Save as and name a new method. 
Equilibrate the system   
1. Turn on Pump, Column heater, Injector, UV detector (it takes around 5 minutes 
for UV detector self calibration), and RI detector. 
2. Open Breeze Software, then click “Manage Breeze”, the bottom one on a left 
panel, then click System to see the software shows all instruments connected, if not, 
restart the software. 
3. Purge the system; Pump, Injector and Detector, by click the middle icon on the 
left hand side of Flow indicator, then follow the screen.  
3.1 The screen will first ask to prime the pumps with the mobile solution. To 
prime the pump, just draw 2-3ml for each pump. Open a reference valve locates 
above “Pump A” maker. Set flow rate and click next. After purging the pump, 
close the reference valve then click next for injector purging.  
3.2 Set flow rate for injector purging. Attached the column at when the flow 
rate reaching the setting rate. (Attached the column at the bottom first to reduce 
the chance that air will go inside the column and damage the packing.) Also place 
the small amount of mobile phase for injector cleaning. 
3.3 Purge the detectors. 
Note: All flow rate setting should be 80-100% of actual flow rate in the Method, 
except for detectors purging, which 1ml/min is the maximum.   
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4. After purging the system, click Equilibrate System icon, a bottom left icon, then 
choose the method from the saved list and run until get a stable base line (between 2-6 
hours depends on the conditions of the Method). 
Note: filter in 
case of DI water and other solution. This is to avoid the system and column getting clot. 
 
Analyze the sample 
1. Place all 0.2
sample for the first sample to be analyzed. For some reason, our machine sometimes 
doesn’t read the first sample correctly. This is important!!!  
2. Set up a Sample Queue. For the first row, choose “Equilibrate” for function, 
choose the method and set 10 minutes for Run Time. 
3. For the second row, choose “Inject Samples”, choose the method, name blank for 
the first sample, then set Runtime and Injection Volume. 
4. Then add all of samples into the sample queue. Make sure each sample is in the 
same vial number with the sample queue. 
5. Click Run Sample icon, the second icon on the left, then name a sample set for 
your own reference. 
 
Turn off the system 
1. Set the flow rate to 0.1ml run the pump if pump already stopped. 
2. Detach the column but detach the top of the column first then the bottom. Again 
this will reduce the chance that air will go into the column. Then stop the pump. 
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3. Turn off everything. 
 
Analyze the data 
1. Click “Find Data” on the left panel. 
2. Choose Sample Set, Sample in Injection Tab, then choose the channel 
3.  Click Integrate icon to get Area Under Curve, Peak Height and Retention time 
for each peak. (Sometime this doesn’t work due to the peak is to low but a line can be 
drawn at the base of the peak to get all of these data.)  
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Appendix B: Tumor Perfusion Calculation by Gamma-Vatiate Function 
For in vivo tumor perfusion, a first-pass kinetics gamma-variate function was 
used. Rissanen et al. [62] showed they can becalculated perfusion by: [Figure B.1] 
             
          
             
        Eq B.1 
and              
            
                 
             Eq B.2 
Because we want to compare perfusion of two agent for the same tumor, so that 
the tissue volume is constant that give us: 
                         
            
                 
          Eq B.3 
which mean we can compare perfusion as a function of blood volume and mean 
transit time. 
 
Figure B.1 First-pass kinetics gamma-variate function and intensity-time curve [62] 
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We can calculate blood volume and mean transit time by gamma-variate function. 
[61] In short, for first-pass kinetics gamma-variate function, we can plot the intensity of a 
signal by: 
             
       
   
 
   
                                  Eq B.4 
where           
   
 
                                                                 Eq B.5 
                           
 
    
                                                                             Eq B.6 
and            
 
   
               Eq B.7 
As you can see from equation B.4 to B.7, every parameters can be calculated by 
guessing only one parameter , except Pmax and tmax are the maximum signal and time at 
maximum signal, respectively. Both values are the values from the experiment.  With f(t) 
best fit by guessing , mean transit time (tmtt) can be calculate from equation B.7 and 
blood volume is the area under curve of gamma-variate function, then the bloof flow can 
be calculate. 
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